By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Alba Therapeutics Corporation 

2400 Boston Street
Suite 302
Baltimore  Maryland  21224  U.S.A.
Phone: 410-319-0780 Fax: 410-319-0834



Company News
Innovate Biopharmaceuticals Completes License For Late-Stage Celiac Disease Asset From Alba Therapeutics Corporation 2/29/2016 6:40:54 AM
Alba Therapeutics Corporation Announces Positive Results Of Phase 2b Trial In Celiac Disease 2/11/2014 7:18:30 AM
Alba Therapeutics Corporation Taps Wendy Perrow to Chief Executive Officer Post 11/6/2013 6:47:09 AM
Alba Therapeutics Corporation Recruiting for a Phase IIb Clinical Trial and Gains Exclusive Rights to the First and Only Patient Reported Outcome Questionnaire for Patients with Celiac Disease 5/1/2012 12:31:24 PM
Cephalon, Inc. (CEPH) Signs Option Agreement to Acquire Assets from Alba Therapeutics Corporation 2/10/2011 8:58:08 AM
Biotech Cash Crunch Leads to Layoffs at Alba Therapeutics Corporation, Novavax, Inc. (NVAX) 1/26/2009 7:52:12 AM
Alba Therapeutics Corporation Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease - Milestone Marks the First Time a European Patient with Active Celiac Disease has Enrolled in a Clinical Trial for an Investigational Medication from Alba Therapeutics 11/11/2008 10:21:04 PM
2008 Mid-Atlantic Bio Exhibitor Profiles 10/21/2008 11:36:47 AM
Alba Therapeutics Corporation Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 10/7/2008 10:43:37 AM
Alba Therapeutics Corporation Announces Promotions 10/3/2008 11:26:14 AM